• P F White and I Smith.
• Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas 75235-9068.
• J Clin Anesth. 1993 Nov 1;5(6 Suppl 1):3S-13S.

AbstractRecent pharmacologic and technologic advances in anesthesia and surgery allow outpatients with complex medical problems to undergo a wide variety of diagnostic and surgical procedures on an ambulatory basis. Increasingly, however, anesthesia practitioners, as well as pharmacy and therapeutic committees, are demanding proof that a new, more costly drug or medical device is superior to existing products in achieving its desired effect, is associated with fewer adverse effects, enhances efficiency, and reduces health care costs. The new field of pharmacoeconomics has emphasized the importance of cost-effectiveness analyses that consider both direct and indirect costs of newer drugs and therapeutic modalities. As new biomedical technology is introduced to facilitate the perioperative management of patients (e.g., computerized anesthesia information management systems), evidence that these systems enhance our ability to continue to provide high-quality, cost-effective health care will assume increasing importance. Limitations in health care resources necessitate a careful reevaluation of our clinical practices with respect to choice of drugs, supplies, equipment, and even discharge criteria. Ambulatory anesthesia and surgery will continue to increase because of the potential cost savings for patients undergoing elective operations on an outpatient basis. However, the challenge we face will be to continue to provide high-quality anesthesia care at a reduced cost. A careful examination of commonly accepted (but unproven) clinical practice patterns will be necessary to meet this challenge.

15 keywords...

hide…